USFDA successfully inspects Alembic’s JV facility Aleor Derma

VADODARA (BARODA) | MUMBAI | RAJKOT – In a press release submitted to the Exchanges in India on Monday, in wee hours before the trading session kicked-off on the Indian Bourses, Alembic Pharmaceuticals Ltd said of Aleor Dermaceuticals Ltd’s facility, getting successfully inspected by USFDA.

Aleor Dermaceuticals Ltd. (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals Ltd. (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has successfully cleared its first United States Food and Drugs Administration (USFDA) inspection, the release said.

The US FDA inspection was of its new formulation manufacturing facility located at Karakhadi, Gujarat, India and the inspection has been carried out successfully, without any observations, the statement read.

The scheduled inspection was carried out between 15th October, 2018 and 19th October, 2018.

Aleor was formed in April 2016 to develop, manufacture and commercialise dermatology products for worldwide markets.

Till date Aleor has filed 6 ANDAs.